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doi:10.1016/j.kjms.2011.09.002Abstract We aimed to investigate which factors are associated with coronary artery lesions
(CALs) during the acute and chronic stages in Taiwanese children with Kawasaki disease (KD).
A total of 216 children with KD were enrolled. Clinical and laboratory data were obtained for
each child within 7 days of illness. The patients were classified into KD children without acute
CALs (nZ 135) and those with acute CALs (nZ 81) according to echocardiography data at Week
2 after treatment. Then, KD children with acute CALs were further divided into those without
chronic CALs (nZ 55) and with chronic CALs (nZ 26) according to annual echocardiography
data. During acute stage of KD, neutrophil count (<54%) [odds ratio (OR)Z 0.44, pZ 0.041];
second dose of intravenous immunoglobulin (IVIG) treatment (ORZ 5.01, pZ 0.009); and
platelet count (400,000) (ORZ 0.42, pZ 0.006) were correlated with the risk of acute CALs.
During chronic stage of KD, age (12e60 months) (ORZ 0.25, pZ 0.042); first dose of IVIG treat-
ment (ORZ 0.12, pZ 0.005); and band count (3%) (ORZ 3.51, pZ 0.032) were correlated
with the risk of chronic CALs. Our results suggest that the effects of neutrophil count, doses
of IVIG treatment, and platelet count on CALs in acute KD are important. Age, doses of IVIG
treatment, and band count are related to the persistence of CALs in chronic stage of KD.
Copyright ª 2011, Elsevier Taiwan LLC. All rights reserved.of Medical Education and Research, Kaohsiung Veterans General Hospital, 386 Ta-Chung 1st Road,
w (L.-P. Ger).
vier Taiwan LLC. All rights reserved.
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Kawasaki disease (KD) is an acute systemic vasculitis with
a predilection for Asian race, which occurs mainly in infants
and children younger than 5 years of age [1]. The annual
incidence of KD in Taiwan is estimated to be 69/100,000
children, the third highest in the world after Japan and
Korea [2e4]. KD is characterized by fever; rash; conjunc-
tivitis; inflammation of the mucous membranes; swollen,
erythematous hands and feet; and cervical adenopathy.
The etiology remains unknown. Treatment with a single
high dose of intravenous immunoglobulin (IVIG) is effective
in resolving the acute inflammation and reducing the risk of
coronary artery lesions (CALs) [5]. However, KD is liable to
be complicated by development of CALs, which develop in
approximately 15e25% of untreated KD children and in
about 5% of those after IVIG therapy [5,6]. KD seems to be
a benign, self-limited illness, but actually it is the leading
cause of acquired heart disease in children. This makes how
to identify patients at risk of CALs an important issue.
Many previous studies have identified putative predic-
tors of CAL development in KD including demographic,
clinical, and laboratory variables. These studies have
identified predictors of poor coronary outcome in KD
patients, including IVIG resistance, low hemoglobin level,
low albumin level, high white blood cell (WBC) count, high
neutrophil count, high C-reactive protein (CRP) level, male
sex, and age younger than 1 year or older than 6 years
[7e12]. In contrast to the aforementioned studies, Honka-
nen et al [13] found that the degree of anemia, platelet
count, erythrocyte sedimentation rate (ESR), and WBC
count were not predictive of coronary artery abnormalities.
Thus, controversy still surrounds some clinical and
laboratory risk factors for CALs in KD. The purpose of this
study was to investigate the association of clinical and
laboratory data with CALs in Taiwanese KD children.
Materials and methods
We performed a retrospective cohort study at the Depart-
ment of Pediatrics, Kaohsiung Veterans General Hospital,
Taiwan. Medical records of all children who received
a diagnosis of KD in our hospital between 1993 and 2009
were reviewed. Medical records were reviewed for age;
sex; presenting symptoms; doses of IVIG treatment (2 g/kg/
dose); IVIG brand (Octagam (Octapharma AG; Lachen,
Switzerland) from 1993 to 2005, Gamimune (Bayer Corpo-
ration; Clayton, NC, USA) from 2005 to 2007, TBSF (CSL
limited; Broadmeadows, Victoria, Australia) from 2008 to
2009); complications; and laboratory data, including base-
line WBC with differential count (neutrophil, lymphocyte,
and band), platelet count, hemoglobin level, alanine
aminotransferase (ALT) level, aspartate aminotransferase
(AST) level, and CRP level within 7 days of illness. A total of
216 children who met the established criteria of acute KD
were enrolled [1]. IVIG resistance was defined as persistent
fever for 3 days after initial IVIG. Then, a second dose of
IVIG (2 g/kg/dose) was administered. All KD children
underwent two-dimensional echocardiography at the time
of diagnosis and again at Week 2, Week 4, and Week 8 after
treatment, and annually in follow-up. The internaldiameter of the coronary arteries was measured and CALs
were defined as follows: coronary arteries were classified
as abnormal if the internal lumen diameter was 3 mm in
children younger than 5 years or 4 mm in children older
than 5 years, if the internal diameter of a segment
measured 1.5 times that of an adjacent segment, or if the
coronary lumen was clearly irregular [14]. The patients
were divided into two groups: those who had no acute CALs
and those who had acute CALs. Those with acute CALs were
further divided into two groups: those without chronic CALs
and those with chronic CALs. Acute CALs were defined as
CALs at Week 2 after treatment in the acute stage, and
chronic CALs were defined as CALs that persisted for 1 year
in the chronic stage. Two senior pediatric cardiologists
assessed the images independently. For evaluation of intra-
and interrater reliabilities, a random sample of 40 patients’
measurements was taken twice on different occasions.
Kappa coefficients were 0.943 (p< 0.001) and 0.914
(p< 0.001) for intra- and interrater reliabilities, respec-
tively. The reliability of band count was assessed by six
laboratory technicians to check 40 different blood samples.
Kappa coefficients were 0.958 (p< 0.001) and 0.939
(p< 0.001) for intra- and interrater reliabilities of band
count, respectively. This study was approved by the Insti-
tutional Review Board of Kaohsiung Veterans General
Hospital.
Statistical analysis
All data are expressed as mean standard deviation.
Demographic and clinical data between patients with/
without CALs were compared by the Chi-square test or
Student t test. The variables associated with CALs were then
included in amultivariate logistic regressionmodel. Ap value
<0.05 was considered statistically significant. The statistical
software package of SPSS (version 12.0; SPSS Inc., Chicago,
IL, USA) was used for all of the statistical analysis.
Results
A total of 216 patients who met the criteria for inclusion
were reviewed. They were studied at a mean follow-up
duration of 5.8 5.1 years after KD. There were 84 girls and
132 boys with a mean age of 27.32 25.53 months, ranging
from 2.07 months to 176.43 months. Eighty-one patients
[male/female (M/F), 55/26; mean age, 28.87 26.15
months] were identified as having acute CALs. The remain-
ing 135 patients (M/F, 77/58; mean age, 26.39 25.20
months) had no CALs. These patients with acute CALs were
further divided into two groups: with chronic CALs (nZ 26;
M/F, 19/7; mean age, 36.9 35.9 months) and without
chronic CALs (nZ 55; M/F, 36/19; mean age, 25.1 19.3
months). None had ruptured or occluded CALs. Baseline
patient demographics are summarized in Table 1.
Age, sex, and doses of IVIG treatment in KD
children with and without CALs
The proportion of older patients (>60 months) in KD chil-
dren with acute CALs was higher than that of those without
acute CALs. The proportion of male patients in KD children
Table 1 Comparisons of demographic and clinical data in KD patients with/without acute CALs and with/without chronic CALs
Factor/
category
KD (nZ 216) KD with acute CALs (nZ 81)
Without acute
CALs (nZ 135)
With acute
CALs (nZ81)
COR (95% CI) pa Without chronic
CALs (nZ 55)
With chronic
CALs (nZ 26)
COR (95% CI) pa
Age (months) 26.4 25.2 28.9 26.1 25.1 19.3 36.9 35.9
12 43 (31.9) 25 (30.9) 1.00 15 (27.3) 10 (38.5) 1.00
12e60 80 (59.3) 42 (51.9) 0.90 (0.49e1.68) 0.746 34 (61.8)) 8 (30.8) 0.35 (0.12e1.07) 0.066
>60 12 (8.9) 14 (17.3) 2.01 (0.80e5.01) 0.136 6 (10.9) 8 (30.8) 2.00 (0.53e7.54) 0.306
Sex
Female 58 (43.0) 26 (32.1) 1.00 19 (34.5) 7 (26.9) 1.00
Male 77 (57.0) 55 (67.9) 1.59 (0.89e2.84) 0.114 36 (65.5) 19 (73.1) 1.43 (0.51e4.01) 0.494
Doses of IVIG treatment
None 27 (20.0) 14 (17.3) 1.00 6 (10.9) 8 (30.8) 1.00
1 102 (75.6) 54 (66.7) 1.02 (0.50e2.11) 0.955 42 (76.4) 12 (46.2) 0.21 (0.06e0.74) 0.015
2 6 (4.4) 13 (16.0) 4.18
(1.31e13.37)
0.016 7 (12.7) 6 (23.1) 0.64 (0.14e2.94) 0.569
CALsZ coronary artery lesions; CIZ confidence interval; CORZ crude odds ratio; IVIGZ intravenous immunoglobulin; KDZ Kawasaki
disease.
Data are presented as mean  standard deviation or n (%).
a p Value is estimated by logistic regression.
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However, there were no significant differences between
the two groups in terms of age and sex. Compared with KD
children without acute CALs, those with acute CALs
received more second doses of IVIG treatment (pZ 0.016).
During follow-up of KD children with acute CALs, there
were significant differences between KD children with and
without chronic CALs in terms of first dose of IVIG treat-
ment (pZ 0.015) (Table 1).
Laboratory findings in KD children with and without
CALs
There were no significant differences between KD children
with and without acute CALs in terms of WBC count; band
count; hemoglobin level; platelet count; and serum levels
of AST, ALT, or CRP. In acute stage, there were significant
differences between the two groups in terms of neutrophil
count (<54%) (pZ 0.030). During follow-up of KD children
with acute CALs, there were no significant differences
between KD children with and without chronic CALs in
terms of WBC count; neutrophil count; lymphocyte count;
hemoglobin level; platelet count; and serum levels of AST,
ALT, or CRP, except for band count (3%) (pZ 0.011)
(Table 2).
Multivariate analysis of demographic and clinical
data for KD patients with/without acute CALs
The factors remaining significantly associated with acute
CALs after multivariate analysis are shown in Table 3. Age
and sex were not significantly associated with the presence
of acute CALs. The second dose of IVIG treatment was
significantly associated with increasing odds of acute CALs[odds ratio (OR)Z 5.01, pZ 0.009]. The neutrophil count
(<54%) and platelet count (400,000/mm3) were signifi-
cantly associated with decreasing odds of acute CALs
(ORZ 0.44, pZ 0.041 and ORZ 0.42, pZ 0.006
respectively).
Multivariate analysis of demographic and clinical
data for KD patients with/without chronic CALs
The factors remaining significantly associated with acute
CALs after multivariate analysis are shown in Table 4. Sex
was not significantly associated with the presence of
chronic CALs. Age (12e60 months) and first dose of IVIG
treatment were significantly associated with decreasing
odds of chronic CALs (ORZ 0.25, pZ 0.042 and ORZ 0.12,
pZ 0.005 respectively). The band count (3%) was signifi-
cantly associated with increasing odds of chronic CALs
(ORZ 3.51, pZ 0.032).
Discussion
Our study demonstrated that neutrophil count, second dose
of IVIG treatment, and platelet count were correlated with
the risk of acute CALs; on the other hand, age, first dose of
IVIG treatment, and band count were correlated with the
risk of chronic CALs. Most previous studies have not classi-
fied CALs into acute and chronic stage and might not
delineate the factors for long-term sequelae of CALs
[7e10]. In this series, the distinction of CALs into acute and
chronic stage is important for the exploration of IVIG
resistance on subsequent remodeling of CALs. Our results
suggest that IVIG-resistant patients might be considered for
more aggressive therapy, such as additional steroids or
infliximab, to prevent CALs in chronic stage [15,16].
Table 2 Distribution and odds ratios for KD patients with/without acute CALs and with/without chronic CALs
Factor/
category
KD (nZ 216) KD with acute CALs (nZ 81)
Without
acute CALs
(nZ 135)
With
acute CALs
(nZ 81)
COR (95% CI) pa Without
chronic CALs
(nZ 55)
With
chronic CALs
(nZ 26)
COR (95% CI) pa
n (%) n (%) n (%) n (%)
White blood cell count (103/mm3)
>15.5 33 (24.4) 28 (34.6) 1.00 19 (34.5) 9 (34.6) 1.00
5.5e15.5 96 (71.1) 53 (65.4) 0.61 (0.34e1.12) 0.111 36 (65.4) 17 (65.4) 1.00 (0.37e2.66) 0.995
<5.5 6 (4.4) 0 (0.0) 0 (0.0) 0 (0.0)
Hemoglobin (g/dL)
<11.5 81 (60.0) 55 (67.9) 1.00 35 (63.6) 20 (76.9) 1.00
11.5e15.5 54 (40.0) 24 (29.6) 0.71 (0.40e1.27) 0.245 19 (34.5) 5 (19.2) 0.53 (0.18e1.52) 0.236
>15.5 0 (0.0) 2 (2.5) 1 (1.8) 1 (3.8)
Polymorphonuclear neutrophil (%)
>62 46 (34.1) 38 (46.9) 1.00 28 (50.9) 10 (38.5) 1.00
54e62 42 (31.1) 25 (30.9) 0.72 (0.37e1.39) 0.327 14 (25.5) 11 (42.3) 2.20 (0.76e6.41) 0.149
<54 47 (34.8) 18 (22.2) 0.46 (0.23e0.93) 0.030 13 (23.6) 5 (19.2) 1.08 (0.31e3.79) 0.908
Lymphocyte (%)
<25 48 (35.6) 35 (43.2) 1.00 24 (43.6) 11 (42.3) 1.00
25e33 37 (27.4) 26 (32.1) 0.96 (0.50e1.87) 0.913 18 (32.7) 8 (30.8) 0.97 (0.32e2.90) 0.956
>33 50 (37.0) 20 (24.7) 0.55 (0.28e1.08) 0.082 13 (23.6) 7 (26.9) 1.18 (0.37e3.76) 0.786
Band (%)
<3 75 (55.6) 39 (48.1) 1.00 32 (58.2) 7 (26.9) 1.00
3e5 33 (24.4) 23 (28.4) 1.35 (0.78e2.34) 0.292 11 (20.0) 12 (46.2) 3.78 (1.36e10.46) 0.011
>5 27 (20.0) 19 (23.5) 12 (21.8) 7 (26.9)
Platelet count (1000/mm3)
>400 49 (36.3) 42 (51.9) 1.00 26 (47.3) 16 (61.5) 1.00
150e400 85 (63.0) 36 (44.4) 0.53 (0.30e0.93) 0.026 27 (49.1) 9 (34.6) 0.56 (0.22e1.45) 0.233
<150 1 (0.7) 3 (3.7) 2 (3.6) 1 (3.8)
Aspartate aminotransferase (U/L)
>55 54 (40.0) 31 (38.3) 1.00 22 (40.0) 9 (34.6) 1.00
15e55 78 (57.8) 45 (55.6) 1.08 (0.61e1.89) 0.801 30 (54.5) 15 (57.7) 1.26 (0.48e3.33) 0.642
<15 3 (2.2) 5 (6.2) 3 (5.5) 2 (7.7)
Alanine aminotransferase (U/L)
>45 71 (52.6) 44 (54.3) 1.00 29 (52.70 15 (57.7) 1.00
5e45 62 (45.9) 33 (40.7) 0.93 (0.54e1.62) 0.805 24 (43.6) 9 (34.6) 0.82 (0.32e2.10) 0.676
<5 2 (1.5) 4 (4.9) 2 (3.60 2 (3.6)
C-reactive protein (mg/dL)
0.6 118 (87.4) 74 (91.4) 1.00 51 (92.7) 23 (88.5) 1.00
<0.6 17 (12.6) 7 (8.6) 0.66 (0.26e1.66) 0.374 4 (7.30 3 (11.5) 1.66 (0.34e8.04) 0.527
CALsZ coronary artery lesions; CIZ confidence interval; CORZ crude odds ratio; KDZ Kawasaki disease.
a p Value is estimated by logistic regression.
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suggested to play a role in KD pathogenesis [17]. An influx of
neutrophils is found in the early stage (7e9 days after KD
onset), with a rapid transition to large mononuclear cells in
concert with lymphocytes and immunoglobulin A plasma
cells [18,19]. Destruction of the internal elastic lamina and,
eventually, fibroblastic proliferation occur at this stage,
resulting in the formation and development of arteritis in
KD. Beiser et al [8] developed an instrument to predict the
development of CALs among KD patients. They constructed
a sequential risk classification instrument based on easilymeasured baseline laboratory test results and temperature,
including neutrophil count, and no patient classified as at
low risk developed CALs [8]. Our finding may be considered
to support their report. Band count 20% in KD has been
considered to be a risk factor for IVIG resistance and CALs
[20]; however, in this series, the band count (3%) was
associated with the risk of chronic CALs. The following
reasons may explain the discrepancy in percent bands
between Tremoulet et al’s [20] study and ours. First, 38.3%
of patients with KD in Tremoulet et al’s [20] study were
IVIG resistant, whereas in ours, 12.2% were IVIG resistant.
Table 3 Multivariate analysis of demographic and clinical data for KD patients with/without acute CALs
Factor/category KD (nZ 216)
Without acute CALs (nZ 135) With acute CALs (nZ 81) OR (95% CI) pa
n (%) n (%)
Age (mo)
12 43 (31.9) 25 (30.9) 1.00
12e60 80 (59.3) 42 (51.9) 0.86 (0.43e1.69) 0.652
>60 12 (8.9) 14 (17.3) 1.77 (0.61e5.17) 0.297
Sex
Female 58 (43.0) 26 (32.1) 1.00
Male 77 (57.0) 55 (67.9) 1.49 (0.81e2.75) 0.205
Doses of IVIG
None 27 (20.0) 14 (17.3) 1.00
1 102 (75.6) 54 (66.7) 1.16 (0.54e2.49) 0.707
2 6 (4.4) 13 (16.0) 5.01 (1.49e16.83) 0.009
Polymorphonuclear neutrophil (%)
>62 46 (34.1) 38 (46.9) 1.00
54e62 42 (31.1) 25 (30.9) 0.88 (0.43e1.81) 0.734
<54 47 (34.8) 18 (22.2) 0.44 (0.20e0.97) 0.041
Platelet count (1000/mm3)
>400 49 (36.3) 42 (51.9) 1.00
150e400 85 (63.0) 36 (44.4) 0.42 (0.23e0.77) 0.006
<150 1 (0.7) 3 (3.7)
CALsZ coronary artery lesions; CIZ confidence interval; IVIGZ intravenous immunoglobulin; KDZ Kawasaki disease; ORZ odds ratio.
a p Value is estimated by logistic regression.
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cally diverse, whereas in ours, they were all Taiwanese [20].
The mechanism of a higher percentage of band count in KD
remains unclear and merits additional investigation.Table 4 Multivariate analysis of demographic and clinical data
Factor/
category
KD with
Without chronic CALs (nZ 55) With chroni
n (%) n
Age (mo)
12 15 (27.3) 10
12e60 34 (61.8) 8
>60 6 (10.9) 8
Sex
Female 19 (34.5) 7
Male 36 (65.5) 19
Doses of IVIG treatment
None 6 (10.9) 8
1 42 (76.4) 12
2 7 (12.7) 6
Band (%)
<3 32 (58.2) 7
3e5 11 (20.0) 12
>5 12 (21.8) 7
CALsZ coronary artery lesions; CIZ confidence interval; IVIGZ intra
a p Value is estimated by logistic regression.Administration of a single high dose of IVIG (2 g/kg) for
10e12 hours is the standard treatment in KD [5]. However,
7.8e38.3% of KD patients are unresponsive to the initial
IVIG treatment [20e25]. In this series, we demonstratedfor KD patients with/without chronic CALs
acute CALs (nZ 81)
c CALs (nZ 26) OR (95% CI) pa
(%)
(38.5) 1.00
(30.8) 0.24 (0.07e0.91) 0.036
(30.8) 1.17 (0.25e5.42) 0.840
(26.9) 1.00
(73.1) 1.71 (0.48e6.12) 0.411
(30.8) 1.00
(46.2) 0.15 (0.03e0.63) 0.010
(23.1) 0.33 (0.06e1.97) 0.226
(26.9) 1.00
(46.2) 3.51 (1.12e11.03) 0.032
(26.9)
venous immunoglobulin; KDZ Kawasaki disease; OR, odds ratio.
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and chronic CALs, as was observed in previous reports
[22e24]. The mechanism of IVIG in reducing inflammation
of KD is not clearly understood. Some scoring systems,
including age; illness duration; platelet count; ESR; and
concentrations of hemoglobin, CRP, lactate dehydroge-
nase, and alanine aminotransferase, had been used as
predictors of IVIG resistance [10,20,24e26]. The predictive
value of these scoring systems, especially the Egami score
system in different ethic groups, is still not widely accepted
[24,26]. Further studies are needed to elucidate the
mechanism of IVIG for identifying new targets for therapy in
IVIG-resistant patients.
Muta et al [9] reported that older children with KD expe-
rienceadelay inbothdiagnosis and treatmentwith IVIG, and,
in children older than 6 years, age is an independent risk
factor for cardiovascular sequelae in KD. Age less than 1 year
is also a risk factor [7,13]. These younger patients often
present with incomplete clinical features, adding difficulty
in making accurate diagnosis and offering timely treatment.
Our analysis of the risk factor of age in chronic KD is
compatible with these previous reports [7,9,13].
Other predictors of poor coronary outcome in KD patients
in previous studies included low hemoglobin level, low
albumin level, high WBC count, high CRP level, and male sex
[7,8,10e12]. Platelet count has been identified as a marker
for increased risk of CALs, but controversy remains regarding
whetherdecreasedor increasedplatelet count is thehigh-risk
factor [7,10e12]. In this series, high platelet count
(>400,000/mm3)was significantly associatedwith high risk of
acute CALs. In contrast to the aforementioned studies, Hon-
kanen et al [13] found that the degree of anemia, platelet
count, ESR, and WBC count were not predictive of CALs.
Several limitations in this study need to be specified.
This study was a single-center retrospective cohort inves-
tigation without a large number of patients. In addition,
these traditional clinical and laboratory markers for
development of CALs need to be evaluated jointly with
novel biomarkers in future studies. In this study, the use of
Japanese Ministry of Health criteria might underestimate
the true incidence of CALs in patients with KD. We could
not rule out the influence of the different brands of IVIG
used to treat patients on outcome. A multicenter cohort
study is therefore suggested for the future.
In conclusion, the results of this study suggest that the
effects of neutrophil count, doses of IVIG treatment, and
platelet count on CALs in acute KD are important. Age,
doses of IVIG treatment, and band count are related to the
persistence of CALs in the chronic stage of KD.
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